Clinical evaluation of giomer-based injectable resin composite versus resin-modified glass ionomer in class V carious lesions over 18 months: A randomized clinical trial.

AIM: This randomized clinical trial aimed to evaluate the clinical performance of giomer-based injectable resin composite (GIRC) versus resin-modified glass ionomer (RMGI) in class V carious lesions over 18 months.

PARTICIPANTS AND

METHODS

Thirty participants with a cervical carious lesion were recruited and allotted to two groups (n = 15); Group 1 received GIRC (Beautifil Flow Plus X F03, Shofu Dental Corporation, Kyoto, Japan), and Group 2 received RMGI (Fuji II LC, GC Corporation, Tokyo, Japan). Materials were placed according to the manufactures' instructions. Restorations were evaluated using the modified United States Public Health Service criteria at baseline, after 6, 12, and 18 months. Data were statistically analyzed with the significance level set at (P ≤ 0.05) where categorical data as frequency, percentage, and intergroup comparisons were performed using the Chi-squared test and intragroup comparison using Cochran's Q-test.

RESULTS

Intergroup and intragroup comparisons showed no statistically significant difference between GIRC and RMGI at different time intervals for marginal adaptation, marginal staining, surface texture, secondary caries, retention, and postoperative sensitivity.

CONCLUSION

GIRC and RMGI showed similar clinical performance and are clinically acceptable after 18-month follow-up period.